Payment overview · 2025
General Payments
$45.48
3 reported records · 3 companies
Healthcare provider profile · identity verified
Scott Edward Davis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HUNTINGTON, WV · NPI 1518171560
Verified facts
What the public records show
CMS Open Payments records show Scott Edward Davis, M.D. received $45.48 in general payments during 2025 across 3 reported records.
GlaxoSmithKline, LLC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.57 | 34.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.02 | 33.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.89 | 32.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.48 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 19 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 149 |
| Omeprazole | Omeprazole | 511 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 492 | 140 |
| Gabapentin | Gabapentin | 445 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 425 | 141 |
| Lisinopril | Lisinopril | 377 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 89 |
| Losartan Potassium | Losartan Potassium | 327 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 319 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 307 | 121 |
| Potassium Chloride | Potassium Chloride | 288 | 80 |
| Metformin Hcl | Metformin Hcl | 286 | 87 |
| Prednisone | Prednisone | 273 | 162 |
| Hydrochlorothiazide | Hydrochlorothiazide | 270 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 83 |
| Furosemide | Furosemide | 267 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 253 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 68 |
| Famotidine | Famotidine | 220 | 67 |
| Montelukast Sodium | Montelukast Sodium | 201 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 188 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 54 |
| Eliquis | Apixaban | 161 | 40 |
| Glipizide | Glipizide | 160 | 45 |
| Carvedilol | Carvedilol | 159 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 42 |
| Trazodone Hcl | Trazodone Hcl | 131 | 32 |
| Ibuprofen | Ibuprofen | 130 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 122 | 35 |
| Ozempic | Semaglutide | 113 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 31 |
| Tramadol Hcl | Tramadol Hcl | 103 | 20 |
| Simvastatin | Simvastatin | 102 | 24 |
| Lovastatin | Lovastatin | 101 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 19 |
| Metformin Hcl Er | Metformin Hcl | 98 | 29 |
| Sertraline Hcl | Sertraline Hcl | 96 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 91 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 25 |
| Allopurinol | Allopurinol | 77 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 27 |
| Alprazolam | Alprazolam | 72 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 72 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 72 | 22 |
| Novolog Flexpen | Insulin Aspart | 67 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 19 |
| Lorazepam | Lorazepam | 63 | suppressed |
| Methocarbamol | Methocarbamol | 63 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 17 |
| Mirtazapine | Mirtazapine | 57 | 20 |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Atenolol | Atenolol | 56 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 41 |
| Meloxicam | Meloxicam | 54 | 18 |
| Celecoxib | Celecoxib | 53 | 20 |
| Buspirone Hcl | Buspirone Hcl | 51 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 51 | 12 |
| Spironolactone | Spironolactone | 51 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 25 |
| Baclofen | Baclofen | 50 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 50 | 11 |
| Naproxen | Naproxen | 48 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Nifedipine Er | Nifedipine | 47 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 46 | 12 |
| Azithromycin | Azithromycin | 45 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Nystatin | Nystatin | 43 | 30 |
| Finasteride | Finasteride | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 20 |
| Sucralfate | Sucralfate | 39 | 12 |
| Cefdinir | Cefdinir | 38 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 14 |
| Nitroglycerin | Nitroglycerin | 38 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Amoxicillin | Amoxicillin | 35 | 29 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 19 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Victoza 3-Pak | Liraglutide | 29 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ibu | Ibuprofen | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Victoza 2-Pak | Liraglutide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.48 · 3 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, QULIPTA, SHINGRIX, UBRELVY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error